NCT02848911 - Safety Study to Assess AFM11 in Patients With Relapsed or Refractory Adult B-precursor ALL | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

April 30, 2019

Conditions

Leukemia, B-Cell

Interventions

DRUG

AFM11

Accelerated-titration dose-escalation with 1 patient per dose-level, followed by standard dose-escalation (3 + 3 design), Treatment duration: 2 weeks

Trial Locations (12)

First Pavlov State Medical University, Saint Petersburg

LKH-Universitätsklinikum Graz, Graz

Kepler Universitätsklinikum Linz, Linz

Uniklinikum Salzburg, Salzburg

University Hospital, Brno

Rambam Medical Center, Haifa

Hadassah Medical Center, Jerusalem

Rabin Medical Center, Petah Tikva

Independent Public Healthcare Municipal Hospital, Chorzów

University Hospital, Krakow

Baranov Republican Hospital, Petrozavodsk

Almazov NW Federal Medical Research Center, Saint Petersburg